Clinical Trial Search

Primary: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Clinical Remission at Week 12 — 15.4; 19.5; 36.6; 28.0 percentage of participants — p=0.0955

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 1; 3; 2; 7 Participants

Primary: Impact of OrCam on Vision-related Quality of Life — 20 Participants

Primary: the Change From Baseline in Cue Nicotine Craving Rating Score — 64; 46 score on a scale

Primary: Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) — 53.3…

Primary: Minutes of Moderate to Vigorous Physical Activity (MVPA) Post-intervention — 3.27; 3.27 mean minutes per hour — p=.207

Primary: Number of Participants With Target Vessel Failure (TVF) — 20; 12 Participants

Primary: Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) — 0; 0; 0; 0 Number of DLTs seen

Primary: Percentage of Negative Urine Cannabinoid Tests During Treatment — 40.9; 27.2 percentage of negative urine tests — p=0.029

Primary: Number of Participants With a Clinically Significant Infection — 12; 14; 5 Participants

Primary: Program Logins Per Participant by Week. — 9.15; 8.17; 3.6; 6.06 number of program logins

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12) — 100; 88 percentage of participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 4 Participants

Primary: Summary of Treatment-Emergent Adverse Events — 13; 5; 5; 3 Participants

Primary: Improved Quality of Care — 45; 68; 53 Participants — p=0.074